Palatin Presents Data From Preclinical Evaluation of PT-15 for Obesity

Palatin Technologies has released data from preclinical studies of PT-15, the Company's novel, small molecule, melanocortin receptor subtype-4 (MC4R) selective agonist that is in development for the treatment of obesity.

The studies entailed peripheral administration of PT-15 to both normal and diet-induced obese rodents. After 11 days of treatment, daily food consumption was reduced by approximately 30 percent to 50 percent, accompanied by up to a 15 percent reduction in body weight. A significant decrease in blood glucose and plasma insulin levels was also observed, along with a reduction in adipose depots.

These findings were not associated with adverse effects such as sickness, taste aversion or disruption of normal behavior. Furthermore, in contrast to most nonselective melanocortin agonists, no erectile activity was observed.